Sagimet Biosciences Inc. - Series A Common Stock, $0.0001 par value per share (SGMT) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2023 to Q4 2025

Type / Class
Equity / Series A Common Stock, $0.0001 par value per share
Symbol
SGMT on Nasdaq
Shares outstanding
31,278,271
Price per share
$5.86
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
14,396,067
Total reported value
$85,225,622
% of total 13F portfolios
0%
Share change
+1,638,323
Value change
+$8,794,108
Number of holders
87
Price from insider filings
$5.86
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Sagimet Biosciences Inc. - Series A Common Stock, $0.0001 par value per share (SGMT) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
AP11 Ltd 4.9% -10% $5,055,597 -$504,198 1,504,642 -9.1% AP11 Limited 24 Jun 2025
Woodline Partners LP 4.8% -44% $10,299,309 -$7,211,088 1,501,357 -41% Woodline Partners LP 30 Sep 2025
Blue Owl Capital Holdings LP 4.3% $4,527,659 1,323,877 Blue Owl Capital Holdings LP 31 Dec 2024

As of 31 Dec 2025, 87 institutional investors reported holding 14,396,067 shares of Sagimet Biosciences Inc. - Series A Common Stock, $0.0001 par value per share (SGMT). This represents 46% of the company’s total 31,278,271 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Sagimet Biosciences Inc. - Series A Common Stock, $0.0001 par value per share (SGMT) together control 41% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
VANGUARD GROUP INC 4% 1,259,550 +4.7% 0% $7,456,536
Blue Owl Capital Holdings LP 4% 1,243,877 -6.4% 2.3% $7,363,752
Affinity Asset Advisors, LLC 3.7% 1,148,245 +228% 0.49% $6,797,610
Woodline Partners LP 3.2% 1,000,943 -33% 0.02% $5,925,583
BAKER BROS. ADVISORS LP 3% 952,996 0% 0.03% $5,641,736
BlackRock, Inc. 2.6% 813,953 +33% 0% $4,818,601
MARSHALL WACE, LLP 2.5% 780,446 0% $4,620,242
HHLR ADVISORS, LTD. 2.3% 724,800 0% 0.14% $4,290,816
Siren, L.L.C. 2.3% 724,771 0% 0.13% $4,290,644
MILLENNIUM MANAGEMENT LLC 1.9% 586,947 -24% 0% $3,474,726
D. E. Shaw & Co., Inc. 1.6% 485,496 -31% 0% $2,874,136
RENAISSANCE TECHNOLOGIES LLC 1.1% 342,500 +112% 0% $2,027,600
Hudson Bay Capital Management LP 0.97% 304,472 0.01% $1,802,474
BRIDGEWAY CAPITAL MANAGEMENT, LLC 0.96% 299,641 0% 0.04% $1,773,875
GEODE CAPITAL MANAGEMENT, LLC 0.95% 295,856 +4.5% 0% $1,752,148
RAYMOND JAMES FINANCIAL INC 0.92% 286,250 +2.9% 0% $1,694,600
Pale Fire Capital SE 0.71% 221,875 0.17% $1,313,500
UBS Group AG 0.65% 201,759 -34% 0% $1,194,413
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.57% 179,024 +450% 0% $1,059,822
Point72 Asset Management, L.P. 0.56% 175,830 0% $1,040,914
Verition Fund Management LLC 0.49% 154,670 0% $915,646
FNY Investment Advisers, LLC 0.46% 142,881 +29% 0.24% $845,000
DIMENSIONAL FUND ADVISORS LP 0.43% 136,039 +437% 0% $805,328
683 Capital Management, LLC 0.4% 126,349 0.06% $747,986
GOLDMAN SACHS GROUP INC 0.4% 125,946 +729% 0% $745,600

Institutional Holders of Sagimet Biosciences Inc. - Series A Common Stock, $0.0001 par value per share (SGMT) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 14,396,067 $85,225,622 +$8,794,108 $5.92 87
2025 Q3 12,635,689 $86,680,189 +$6,909,222 $6.86 72
2025 Q2 11,676,267 $88,988,335 +$3,493,936 $7.62 67
2025 Q1 13,776,513 $44,920,783 -$15,209,275 $3.26 69
2024 Q4 17,500,774 $78,763,978 -$8,862,770 $4.50 66
2024 Q3 19,656,790 $54,446,688 -$7,224,186 $2.77 63
2024 Q2 20,925,200 $71,568,836 -$7,461,714 $3.42 81
2024 Q1 22,609,183 $122,544,913 +$44,339,223 $5.42 81
2023 Q4 14,445,035 $76,118,157 -$8,948,267 $5.42 51
2023 Q3 11,717,467 $103,113,019 +$103,113,019 $8.80 47